Sponsors Often Compromise Ethics For Cost Efficiency With Trial Outsourcing
This article was originally published in PharmAsia News
Executive Summary
As drug sponsors opt to cut costs by outsourcing clinical trials to emerging nations such as India, incomplete patient consent forms are one of several rising ethical concerns linked to such demand
You may also be interested in...
India Ready For Chemistry Outsourcing, Wyeth Says; Biology Remains In West
India is currently a viable option for simple chemistry outsourcing and offshoring; however, additional skill development is needed before medicinal chemistry and biology operations can be conducted there, speakers said at the Financial Times Global Pharmaceuticals & Biotechnology conference in London Sept. 18
Wyeth’s R&D Strategy: Spoonfuls Of Enrollment With A Dash Of Outsourcing
Wyeth research and development efforts are focusing on global patient enrollment as a key method to accelerate the drug development process
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).